Roche
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion
November 29, 2018Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion
The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …
Roche’s Genentech to acquire inflammatory drug discovery firm Jecure
November 28, 2018Research and Development, Sales and Marketing Genentech, Jecure, Roche, liver disease, nash, pharma
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of …
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma
November 19, 2018Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …
Roche’s eye drug beats Lucentis at Phase 2 in wet age-related macular degeneration
October 29, 2018Research and Development, Sales and Marketing Genentech, Lucentis, Roche, eyecare, faricimab, pharma
Roche has revealed positive new Phase 2 data for faricimab (RG7716) in the treatment of neovascular (“wet”) age-related macular degeneration …
Roche’s Alecensa topples Pfizer’s Xalkori in Asian patients with ALK+ advanced lung cancer
October 23, 2018Manufacturing and Production, Research and Development Alecensa, Cancer, ESMO 2018, Roche, lung cancer, pharma
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small …
Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer
October 22, 2018Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq
Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society …
Roche signs $1 billion deal with cell therapy firm SQZ biotech
October 17, 2018Research and Development Roche, SQZ, collaboration, deal, oncology
The Massachusetts-based cell therapy company SQZ Biotech, has announced the expansion of its collaboration with Swiss pharma giant Roche, in …
Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk
October 16, 2018Manufacturing and Production, Sales and Marketing Cancer, Kadcyla, Roche, breast cancer, pharma
Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early …
Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS
October 11, 2018Research and Development Ocrevus, Roche, multiple sclerosis, pharma
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …
Celltrion’s Rituxan biosimilar gets unanimous backing from FDA committee
October 11, 2018Sales and Marketing FDA, Oncologic Drugs Advisory Committee, Rituxan, Roche, Truxima
FDA approval looks to be in reach for Celltrion, as an advisory committee for the US regulator voted unanimously to …
FDA expands indication of Roche’s Hemlibra in haemophilia
October 5, 2018Medical Communications, Sales and Marketing Hemlibra, Roche, haemophilia, pharma
The FDA has chosen to expand the label of Roche’s Hemlibra (emicizumab-kxwh), approving it for routine prophylaxis to prevent the …
Roche’s flu drug speeds up recovery in Phase III trial
October 4, 2018Research and Development Roche, drug, flu, pharma, recovery
Swiss multinational Roche’s flu drug baloxavir marboxil significantly sped up recovery time in comparison with placebo, in people at high …
Roche acquires immuno-oncology biotech Tusk in €655m deal
October 1, 2018Sales and Marketing Droia, Roche, Tusk, immuno-oncology, immunology, oncology
Swiss multinational Roche has acquired the privately held immuno-oncology company Tusk Therapeutics in a deal that could be worth up …
Roche’s Tecentriq+chemo combo shows first-line benefit in small cell lung cancer
September 26, 2018Research and Development Cancer, Combo, Roche, chemotherapy, lung cancer, pharma, tecentriq
Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy …
Roche’s entrectinib shrinks lung tumours with two-year response duration
September 25, 2018Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib
Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
